Trials Open to Enrollment

AIDS Clinical Trials: New Trials Open to Enrollment

http://www.actis.org/actinewl.htmi

f A Phase II, Double-Blind Trial of Recombinant Human Nerve Growth Factor for Treatment
of HIV-Associated Sensory Neuropathy. NIAID ACTG 291. Drug: Recombinant human
nerve growth factor.
The purpose of this AIDS Clinical Trials Group study is to assess the efficacy, safety, and
tolerability of recombinant human nerve growth factor (rhNGF) in the treatment of HIV-associated
sensory neuropathy. Nerve growth factor is important in the development and maintenance of
sympathetic and sensory neurons and their outgrowths, it is proposed that recombinant human
nerve growth factor may provide a specific restorative treatment for HIV-associated painful
sensory neuropathy. For more information, view the Protocol Database record.
E A Randomized Phase Iii Trial of Oral Isotretinoin Versus Observation for Low-Grade
Cervical Dysplasia in HIV-Infected Women. NIAID ACTG 293. Drug: Isotretinoin.
The purpose of this AIDS Clinical Trials Group study is to determine the efficacy of oral
isotretinoin in preventing progression of mild cervical dysplasia (grade I cervical intraepithelial
neoplasia, i.e., CIN I) to a more severe cervical dysplasia (i.e., CIN II, CIN III, or invasive cancer)
in patients receiving treatment versus observation only. To assess the adverse effects and toxicity
of oral isotretinoin in HIV-infected women. Cervical neoplasia is frequently seen in HIV-infected
women, apparently resulting from immunosuppression and common risk factors, including sexual
behavior patterns. For more information, view the Protocol Database record.
SA Pilot Study of Stem Cell Mobilization and Harvesting From the Peripheral Blood Using
Filgrastim. NIAID ACTG 285. Drug: Filgrastim.
The purpose of this AIDS Clinical Trials Group study is to determine the safety of stem cell
harvesting after administration of filgrastim (G-CSF) to mobilize bone marrow stem cells into the
peripheral blood in patients at various stages of HIV-1 infection as well as in HIV-negative
volunteers. It is also to determine the surface phenotypic and functional characteristics as well as
the viral load in the stem cells obtained following this procedure. For more information, view the
Protocol Database record.
o A Phase II, Randomized Multicenter Open Label Study of Subcutaneous Interleukin-2
(Aldesleukin) With Standard of Care Antiviral Therapy Versus Standard of Care Antiviral
Therapy Alone in HIV Seropositive Patients With CD4 Counts of 200-500 cells/mm3. NMAID
96 1-46. Drug: Aldesleukin.
The purpose of this National Institute of Allergy & Infectious Diseases study is to evaluate the
effect on immunological markers of subcutaneous aldesleukin (interleukin-2; I-2) plus antiviral
therapy versus antiviral therapy alone in HIV-infected patients and to assess the tolerability and
toxicity of these regimens. In previous studies, 11-2, a protein produced naturally by lymphocytes,
has resulted in improvement of some immunologic functions and increases in CD4 count in some
HIV-infected patients. Although side effects occur, most resolve within days after drug
administration. For more information, view the Protocol Database record.
DA Multicenter, Double-Blind, Phase HI, Adjuvant-Controlled Study of the Effect of 10 Units
of HIV-1 Immunogen Compared to Incomplete Freund's Adjuvant (IFA) Alone Every 12
Weeks on AIDS-Free Survival in Subjects with HIV Infection and CD4 T-Lymphocytes

8 of 10

03/17/97 15:07:16